Rhenman & Partners Asset Management AB Purchases 43,000 Shares of Biogen Inc. $BIIB

Rhenman & Partners Asset Management AB lifted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 358.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 55,000 shares of the biotechnology company’s stock after purchasing an additional 43,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $7,704,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Empowered Funds LLC raised its position in Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth grew its holdings in shares of Biogen by 172.2% during the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after purchasing an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Biogen in the second quarter valued at approximately $216,000. Envestnet Asset Management Inc. increased its stake in shares of Biogen by 7.2% in the second quarter. Envestnet Asset Management Inc. now owns 56,076 shares of the biotechnology company’s stock valued at $7,043,000 after buying an additional 3,782 shares during the period. Finally, Assetmark Inc. raised its holdings in Biogen by 1,669.5% in the 2nd quarter. Assetmark Inc. now owns 1,681 shares of the biotechnology company’s stock valued at $211,000 after buying an additional 1,586 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Wall Street Analyst Weigh In

BIIB has been the topic of a number of research reports. Stifel Nicolaus boosted their target price on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Citigroup lifted their price target on shares of Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Tudor Pickering set a $201.00 price objective on shares of Biogen in a research note on Monday, February 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Finally, UBS Group began coverage on Biogen in a research report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 target price for the company. Twelve investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $205.04.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen will present new spinal muscular atrophy (SMA) data, including long‑term high‑dose nusinersen results and Phase 1b salanersen data as Phase 3 studies begin — news that supports the company’s SMA pipeline and could boost long‑term revenue potential if later trials read out favorably. Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
• Positive Sentiment: The New England Journal of Medicine published first data suggesting disease‑modifying potential for zorevunersen (Stoke Therapeutics collaboration) in Dravet syndrome, supporting the ongoing global Phase 3 EMPEROR study — a favorable scientific read that can increase confidence in Biogen’s partnered pipeline assets. The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
• Positive Sentiment: Proposed legislation (H.R. 7336, the ALS Better Care Act) would expand Medicare coverage and payments for ALS‑related services and incentivize clinical trial participation — a policy tailwind that could improve access and reimbursement for ALS therapies and indirectly benefit Biogen’s neurology franchise. New Bill: Representative Janice D. Schakowsky introduces H.R. 7336: ALS Better Care Act
• Neutral Sentiment: Analyst / investor pieces and fund letters have highlighted Biogen as an attractive long‑term holding (coverage in InsiderMonkey/Yahoo) — supportive for investor interest but not an immediate catalyst. What Makes Biogen (BIIB) an Attractive Long-Term Holding?
• Neutral Sentiment: Recent short‑interest reports show anomalous data (zero shares / NaN increases and a days‑to‑cover of 0.0), indicating reporting noise rather than a clear short‑selling pressure signal — treat these items as unreliable until clarified. (Internal short‑interest entries)
• Negative Sentiment: Despite positive pipeline and data releases, shares are down today — likely reflecting profit‑taking after recent gains, thin trading (volume below recent average), and market focus on near‑term revenue/guidance rather than later‑stage trial data. No new negative company‑specific regulatory or financial disclosures were reported in the entries provided.

Biogen Trading Down 1.7%

Shares of BIIB stock opened at $184.87 on Friday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The stock has a 50 day simple moving average of $183.08 and a two-hundred day simple moving average of $165.27. The company has a market cap of $27.13 billion, a P/E ratio of 20.98, a PEG ratio of 1.47 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.